Acarix accelerates US commercialization into 30 additional states
Kurs
+10,02%
Likviditet
5,26 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-12 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-06 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-21 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-16 | N/A | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2025-05-15 | N/A | Årsstämma |
| 2025-05-12 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-07 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-15 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2024-05-14 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-21 | - | Extra Bolagsstämma 2024 |
| 2024-02-15 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-28 | - | Extra Bolagsstämma 2023 |
| 2023-08-31 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2023-05-11 | - | Årsstämma |
| 2023-05-11 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-11-16 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2022-05-11 | - | Årsstämma |
| 2022-05-11 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-11-23 | - | Extra Bolagsstämma 2021 |
| 2021-11-11 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2021-05-11 | - | Årsstämma |
| 2021-05-11 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-11-12 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-08-11 | - | Extra Bolagsstämma 2020 |
| 2020-05-15 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2020-05-14 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-20 | - | Bokslutskommuniké 2019 |
| 2019-11-14 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-21 | - | Kvartalsrapport 2019-Q2 |
| 2019-08-16 | - | Extra Bolagsstämma 2019 |
| 2019-05-17 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2019-05-16 | - | Årsstämma |
| 2019-05-16 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-20 | - | Bokslutskommuniké 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-24 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2018-05-23 | - | Årsstämma |
| 2018-05-23 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-26 | - | Bokslutskommuniké 2017 |
| 2017-11-14 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-24 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-26 | - | X-dag ordinarie utdelning ACARIX 0.00 SEK |
| 2017-05-24 | - | Årsstämma |
| 2017-05-24 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-23 | - | Bokslutskommuniké 2016 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Acarix, a leader in acoustic and AI-based cardiac diagnostics, today announced a strategic sales partnership with CompleMed, LLC, a national sales organization focusing on the US cardiology market. This partnership expands Acarix sales organization with 16 additional sales teams covering initially 30 new states across the United States, reaching a current geographic market coverage of 43 states.
"We are thrilled to be collaborating with Acarix, whose reputation in the US market continues to grow”, stated Mike Buie, President of CompleMed. “The CADScor System has captured our attention as an exceptional solution for early assessment of patients with non-acute chest pain, which is an increasingly complex and resource demanding issue in the US healthcare system. We look forward to making a difference together with the Acarix team."
"We are excited to announce our new partnership with CompleMed, whose sizeable and capable sales team will enable us to expand our geographic coverage rapidly into additional states. We are eager to expand our US footprint to continue to build on our momentum and bring the CADScor System to even more patients. This well-planned expansion aligns well with our growth strategy and reaffirms our commitment to delivering exceptional care to patients." said Acarix President & CEO, Helen Ljungdahl Round.
For more information contact:
Helen Ljungdahl Round, CEO, phone +1 267 809 1225, +46 730 770283, email helen.round@acarix.com
Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com
About Acarix
| Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor System uses advanced acoustics and AI-technology to rule out CAD non-invasively in less than 10 minutes, with at least 96% certainty. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, certifiedadviser@redeye.se) is Certified Advisor of Acarix. For more information, please visit www.acarix.com. |